Revvity CCL2 (human) LANCE Ultra TR-FRET Detection Kit; 500 assay points

Revvity The LANCE Ultra Human CCL2/MCP-1 Detection Kit is designed for detection and quantitation of human CCL2/MCP-1 in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay. The 500 point kit contains enough reagents to run 500 wells in 384-well format, using a 20 uL reaction volume (15 uL of sample). The 5,000 point kit contains enough reagents to run 5,000 wells in 384-well format, using a 20 uL reaction volume (15 uL of sample). No-wash steps, no separation steps TR-FRET technology Sensitive detection High reproducibility Faster time-to-results Easy automation 96-well, 384-well, and 1536-well formats LANCE and LANCE (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (10 nm). This results in the emission of light at 665 nm. C-C motif chemokine 2 (CCL2) or Monocyte Chemoattractant Protein 1 (MCP1) contains 76 amino acids and is glycosylated after complete processing. CCL2 is part of the CXC subfamily of cytokines. Fibroblasts, tumor cells, smooth muscle cells, endothelial cells, and mononuclear phagocytes can produce CCL2 either constitutively or upon stimulation. CCL2 displays chemotactic activity for monocytes and basophils, but not for neutrophils or eosinophils. It also regulates adhesion molecule expression and cytokine production in human monocytes. CCL2 has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis and atherosclerosis. CCL2 is considered as an important biomarker in cardiovascular diseases. - PEMSD